Report Detail
U.S. Markets for Pharmacologic and Device-Based Approaches to Pain Management, April 2016
More than 40% of people in the U.S. say they have experienced recent pain, with 8% suffering from chronic pain. Direct healthcare costs associated with the treatment of pain total nearly $300 billion annually, with indirect costs such as reduced worker productivity contributing another $300 billion in costs. Multidisciplinary pain management plans may involve the use of pharmacologic, device-based, or alternative therapies; a combination of these modalities often is required to achieve optimum pain relief, particularly for those suffering from chronic pain.
This new report by Medtech Insight presents a detailed overview of the U.S. pain management market. Major topics covered by this report include nonprescription analgesics (e.g., systemic drugs such as acetaminophen and NSAIDs, as well as topical drugs such as amino acids and esters, capsaicin, and methyl and trolamine salicylates), prescription analgesics (e.g., prescription NSAIDs, opioids, combination drugs, antimigraine drugs, adjuvant analgesics, and anesthetics), electrical stimulators (e.g., TENS units and neurostimulators such as occipital nerve, neuromuscular, and spinal cord stimulators), and infusion pumps (e.g., implantable and external pumps).